Posts by Udo Hoffmann, MD
Discordance Across High-Sensitivity Troponin Assays Can Affect Management of Suspected ACS
Júlia Karády, MD, and Udo Hoffman, MD, MPH, of the Cardiovascular Imaging Research Center, observed marked discordance between high-sensitivity cardiac troponin assays that would lead to different management of patients with suspected acute coronary syndrome who had an inconclusive initial evaluation.
Anatomic Versus Functional Testing in Patients with Suspected Coronary Artery Disease
A Massachusetts General Hospital team reported on the advantages of using anatomic assessment of CAD with coronary CT angiography versus functional assessment of myocardial ischemia with stress testing. Here,Júlia Karády, MD, describes the findings of the study.
Immune Checkpoint Inhibitor Therapy Increases Risk of Atherosclerotic Cardiovascular Events
Massachusetts General Hospital researchers have found that patients treated with immune checkpoint inhibitors have higher rates of atherosclerotic cardiovascular events than other cancer patients, but the risk may be modifiable.
Using Chest X-Rays, Artificial Intelligence Can Predict Risk of Lung Cancer
Massachusetts General Hospital researchers have reported a deep learning approach to identify high-risk smokers who should undergo lung cancer screening.
Review: CT-based Computational Modeling to Identify High-Risk CAD
High-risk plaques destined to cause acute coronary syndrome can be identified using coronary computed tomographic (CT) angiography and computational fluid dynamics.
Gaps Remain in Preventative Care of Patients With Nonobstructive CAD Discovered in ED Visits
Researchers at Massachusetts General Hospital have become the first to study both hospital and long-term outpatient management after nonobstructive coronary artery disease is detected by computed tomography angiography performed in the emergency department.
Coronary Artery Disease - Reporting & Data System (CAD-RADS)
Massachusetts General Hospital clinicians discuss a male age 55 that presents with left sided chest pain and has a history of hypertension and hyperlipidemia.
Dr. Hoffmann went to medical school in Leipzig, Germany and completed radiology residency in Vienna, Austria. In 2001, Dr. Hoffmann joined the MGH for a fellowship in cardiovascular imaging and since 2011 is the Chief of Cardiovascular Imaging, the Director of the Cardiac MR PET CT Program.
Dr. Hoffmann is a Professor of Radiology at Harvard Medical School and leads a multidisciplinary group focused on utilizing advanced imaging to improve prevention, diagnosis, and treatment of disease. Dr. Hoffmann is the Director of an NHLBI T32 program in Cardiac Imaging and has trained more than 100 researchers and clinicians. He has lead hallmark clinical trials in cardiovascular imaging such as ROMICAT I and II, PROMISE, and REPRIEVE and leads CT imaging in the Framingham Heart Study. He has published >400 peer reviewed publications and is an Associate Editor for Circulation Cardiovascular Imaging, the Co-Chair of the Imaging Oversight Committee of the Framingham Heart Study, and a member of multiple national initiatives, guideline committees, and task forces for the major cardiology and radiological societies.